Market News AIOpen the app

Unicycive Therapeutics shared its third quarter results and said the FDA accepted its drug application.

ResultsRead the original at SEC EDGAR
Good for UNCY

The FDA accepted OLC's resubmitted application, and CMS added $12.85 per treatment to dialysis providers' base payment for binders. This favors UNCY, but approval and separate payments are not assured, and an earlier FDA letter cited manufacturing problems.

UNCY · Unicycive Therapeutics, Inc.

AI read · Good for UNCY

The AI's read

That brings OLC closer to a possible launch. The earlier FDA letter focused on manufacturing, not drug safety or whether it works, and the resubmission includes data from a new supplier. CMS's payment change may help providers use phosphate binders. Still, the FDA must approve OLC, and separate payments require CMS confirmation.

Get alerts for UNCY

Follow Unicycive Therapeutics, Inc. (UNCY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for UNCY
Free on the App Store and Google Play, or on the web.